Insmed Incorporated — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone fourth-quarter filing. Insmed is a clinical-stage biopharmaceutical company focused on rare diseases; it had no material revenue and was not profitable.
Business context and pipeline
- ARIKAYCE: Lead candidate for adults with treatment-refractory NTM lung disease caused by MAC. The global Phase 3 CONVERT study completed enrollment in Q4 2016. Management expected Month 6 primary-endpoint results in the second half of 2017 and planned to seek U.S. accelerated approval if results supported an application.
- INS1007: Global rights acquired from AstraZeneca in October 2016; development planned initially for non-CF bronchiectasis. Insmed expected to submit an IND and begin a Phase 2 study in 2017.
- INS1009: Phase 1 completed; management was evaluating whether and how to advance the inhaled treprostinil-prodrug candidate.
Financial results and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 reported | $0 reported |
| Research and development expense | $122.7 million | $74.3 million |
| General and administrative expense | $50.7 million | $43.2 million |
| Operating loss | $173.4 million | $117.5 million |
| Net loss | $176.3 million | $118.2 million |
| Basic and diluted loss per share | $2.85 | $2.02 |
| Net cash used in operating activities | $146.7 million | $100.7 million |
| Cash and cash equivalents at year-end | $162.6 million | $282.9 million |
| Working capital at year-end | $140.4 million | $265.9 million |
| Long-term debt, net | $54.8 million | $22.0 million |
There were no meaningful operating margins because the company reported no revenue and incurred operating losses. The filing reports no material product sales; limited French early-access product revenue was immaterial and recorded in other income, rather than revenue.
Operating cash use increased as clinical, regulatory and pre-commercial spending grew, including the $30.0 million AstraZeneca upfront license payment. Investing cash use was $4.2 million, principally for facility build-out; financing provided $30.7 million, including $30.0 million of debt proceeds. Management stated that year-end cash was expected to fund operations for at least 12 months, while also anticipating a need for additional capital.
Material changes versus 2015
- Net loss widened by $58.1 million. R&D expense rose $48.4 million, principally from the $30.0 million INS1007 license payment, higher CONVERT-related clinical costs and increased compensation. G&A expense rose $7.5 million, including increased pre-commercial, legal and consulting costs.
- Cash and cash equivalents fell $120.3 million, while operating cash use increased $46.0 million.
- Debt increased after Insmed amended its Hercules facility and borrowed an additional $30.0 million, bringing principal commitments and borrowings to $55.0 million.
- Quarterly Q4 net loss was $68.4 million, versus $31.2 million in Q4 2015; Q4 2016 included the $30.0 million AstraZeneca upfront payment.
Outlook, risks and unusual items
- Management expected continued operating losses and increased 2017 spending on CONVERT, ARIKAYCE commercialization preparation and INS1007 development. No revenue or earnings guidance was provided.
- The prior Phase 2 ARIKAYCE study did not meet its prespecified primary endpoint for statistical significance (p=0.072), although a key secondary culture-conversion endpoint favored ARIKAYCE (p=0.003). CONVERT results remained a key development and funding catalyst.
- The EMA concluded the submitted evidence was insufficient to support approval; Insmed withdrew its European marketing application in June 2016 and planned to resubmit when more clinical data were available.
- Key risks include clinical-trial and regulatory failure or delay, uncertain reimbursement and adoption, reliance on third-party manufacturers and PARI as the sole nebulizer supplier, future financing needs, and potential dilution. The Hercules loan carries a minimum-cash covenant of $25.0 million, restrictive covenants and a lien on assets other than intellectual property.
- A shareholder class action alleges misleading disclosures concerning ARIKAYCE development and the European application, as well as the Phase 2 study and 2015 offering. Insmed disputed the allegations and intended to defend the case; the outcome and potential cost were uncertain.
- The filing reported an unqualified audit opinion and management and auditor conclusions that internal control over financial reporting was effective as of December 31, 2016.
Most important facts for investors to verify
- CONVERT Month 6 results, the culture-conversion outcome and whether regulators accept the endpoint and data for an NDA or accelerated approval.
- Cash runway against the stated 12-month expectation, ongoing cash burn, financing plans and compliance with the Hercules minimum-liquidity covenant.
- INS1007 Phase 2 timing, development costs and contingent AstraZeneca obligations: up to $85.0 million for milestones for the initial indication, additional milestones for a second indication, and sales-based royalties.
- European regulatory strategy following the withdrawn MAA, and any new clinical evidence required for resubmission.
- Developments in the shareholder litigation, ARIKAYCE and nebulizer supply readiness, and potential share dilution from outstanding equity awards or future financing.